160 related articles for article (PubMed ID: 16421119)
21. IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis.
Waubant E; Gee L; Miller K; Stabler G; Goodkin D
J Interferon Cytokine Res; 2001 Mar; 21(3):181-5. PubMed ID: 11331041
[TBL] [Abstract][Full Text] [Related]
22. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
23. Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy.
Castellazzi M; Bellini T; Trentini A; Delbue S; Elia F; Gastaldi M; Franciotta D; Bergamaschi R; Manfrinato MC; Volta CA; Granieri E; Fainardi E
Dis Markers; 2016; 2016():8434209. PubMed ID: 27340316
[TBL] [Abstract][Full Text] [Related]
24. Reference intervals of plasma matrix metalloproteinases 2, 3, and 9 and serum asymmetric dimethylarginine levels.
Kusnierova P; Vsiansky F; Pleva L; Plevova P; Safarcik K; Svagera Z
Scand J Clin Lab Invest; 2015 Oct; 75(6):508-13. PubMed ID: 26151887
[TBL] [Abstract][Full Text] [Related]
25. The Role of Matrix Metalloproteinase 3 and 9 in the Pathogenesis of Acute Neuroinflammation. Implications for Disease Modifying Therapy.
Ljubisavljevic S; Stojanovic I; Basic J; Vojinovic S; Stojanov D; Djordjevic G; Pavlovic D
J Mol Neurosci; 2015 Aug; 56(4):840-847. PubMed ID: 25702136
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinases and their tissue inhibitors in relapsing remitting multiple sclerosis: Possible markers and treatment agents.
Sanli A; Ozturk M; Soysal A; Doventas Y; Basoglu F; Gozubatik-Celik GR; Baybas S
Ideggyogy Sz; 2021 Jan; 74(1-2):50-56. PubMed ID: 33497055
[TBL] [Abstract][Full Text] [Related]
27. Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients.
Trentini A; Castellazzi M; Cervellati C; Manfrinato MC; Tamborino C; Hanau S; Volta CA; Baldi E; Kostic V; Drulovic J; Granieri E; Dallocchio F; Bellini T; Dujmovic I; Fainardi E
Dis Markers; 2016; 2016():3672353. PubMed ID: 27555667
[TBL] [Abstract][Full Text] [Related]
28. Matrix metalloproteinases as novel disease markers in Takayasu arteritis.
Matsuyama A; Sakai N; Ishigami M; Hiraoka H; Kashine S; Hirata A; Nakamura T; Yamashita S; Matsuzawa Y
Circulation; 2003 Sep; 108(12):1469-73. PubMed ID: 12952836
[TBL] [Abstract][Full Text] [Related]
29. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.
Goldbach-Mansky R; Lee JM; Hoxworth JM; Smith D; Duray P; Schumacher RH; Yarboro CH; Klippel J; Kleiner D; El-Gabalawy HS
Arthritis Res; 2000; 2(2):145-53. PubMed ID: 11062605
[TBL] [Abstract][Full Text] [Related]
30. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment.
Avolio C; Filippi M; Tortorella C; Rocca MA; Ruggieri M; Agosta F; Tomassini V; Pozzilli C; Stecchi S; Giaquinto P; Livrea P; Trojano M
Mult Scler; 2005 Aug; 11(4):441-6. PubMed ID: 16042227
[TBL] [Abstract][Full Text] [Related]
31. Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients.
Nazdik MK; Taheri M; Sajjadi E; Arsang-Jang S; Koohpar ZK; Inoko H; Sayad A
Hum Antibodies; 2016; 24(3-4):65-70. PubMed ID: 27689613
[TBL] [Abstract][Full Text] [Related]
32. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis.
Yushchenko M; Mäder M; Elitok E; Bitsch A; Dressel A; Tumani H; Bogumil T; Kitze B; Poser S; Weber F
J Neurol; 2003 Oct; 250(10):1224-8. PubMed ID: 14586607
[TBL] [Abstract][Full Text] [Related]
33. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
34. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
Horstmann S; Kalb P; Koziol J; Gardner H; Wagner S
Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822
[TBL] [Abstract][Full Text] [Related]
35. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinase-7, matrix metalloproteinase-9, and disease activity in pediatric multiple sclerosis.
Yılmaz U; Gücüyener K; Gürkaş E; Demir E; Serdaroğlu A; Atak A; Aral A; Oner YA
Pediatr Neurol; 2013 Mar; 48(3):255-6. PubMed ID: 23419482
[No Abstract] [Full Text] [Related]
37. [Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis].
Fiedorczyk M; Klimiuk PA; Sierakowski S; Domysławska I; Chwiećko J
Przegl Lek; 2005; 62(12):1321-4. PubMed ID: 16786739
[TBL] [Abstract][Full Text] [Related]
38. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis.
Bar-Or A; Nuttall RK; Duddy M; Alter A; Kim HJ; Ifergan I; Pennington CJ; Bourgoin P; Edwards DR; Yong VW
Brain; 2003 Dec; 126(Pt 12):2738-49. PubMed ID: 14506071
[TBL] [Abstract][Full Text] [Related]
39. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.
Huang CY; Wu TC; Lin WT; Leu HB; Lin CP; Lin SJ; Chen JW
Eur J Clin Invest; 2006 Feb; 36(2):76-84. PubMed ID: 16436088
[TBL] [Abstract][Full Text] [Related]
40. Analysis of MMP2-1306C/T and TIMP2G-418C polymorphisms with relapsing remitting multiple sclerosis.
Aksoy D; Ateş Ö; Kurt S; Çevik B; Sümbül O
J Investig Med; 2016 Aug; 64(6):1143-7. PubMed ID: 27174941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
